Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you for all your efforts
to the folks with law experience: unless generics believe they have this 100% locked up, wouldn’t a settlement still make a tremendous amount of sense for both sides if we were able to get the judgement vacated somehow?
I’m exaggerating, but even if AMRN had to pay 100 million to settle, wouldn’t each party walk away more than satisfied ?
In a way, I guess i’m viewing the generics district court win as leverage for them to essentially “name their price”... I could be totally wrong. Very curious to hear opinions.
The plan going into reviewing Hikma $AMRN brief was the faster I saw “Mori”, the worse the brief. Mori appeared in second paragraph of page 1. Also, very first sentence & last sentence of Paragraph 2 are misleading.
— Dr. Zoidberg 🇺🇦 (@psuvafan007) June 18, 2020
RED = False. GREEN = True. YELLOW = Maybe. GREY = Irrelevant. pic.twitter.com/3z4KFNHJnw
How many errors does it take to mount to harm? How many times in their brief did they acknowledge errors?
Can someone please post the brief, thanks in advance.
Can someone please post a link to the brief
11:59pm
Barring any conflicts of interest, is there a greater chance the same 3 are selected given the similarities in cases ?
If i understand correctly, it’s not exactly a “random” 3 judges selected.
Anyone know off hand which organizations filed Amicus briefs in Cyclobenzaprine case ? If any? Just curious
They are extremely private. Not sure they even have a website, let alone a twitter.
I’m pretty sure generic briefs are due 6/16
You’re saying he did not notify Amarin before releasing paper?
I doubt he would have attached his name to it without them knowing
Question for the lawyers. Can amicus briefs in favor of amarin be filed after generics brief ? Also can amicus briefs follow Amarin’s final brief?
Do we all have good cause to assuage those worries or just you?
White chocolate ? Is that you?
LOL they have to be kidding with that price
Thanks for sharing. If i remember correctly, i came across a post about a month ago that stated Dyk may recuse himself due to prior involvement with Fish and Richardson?
Prayers for you and your family.
Thanks , makes sense!
Shot in the dark here— any chance vascepa can become OTC ?
Not sure if this has been posted yet... he accidentally posted a duplicate image in first post.
Attached both links
FWIW: The $AMRN "genetic logjam" argument for severe hyperglyceridemia. Enzymatic logjam happens between VLDL --> IDL (big red arrow, upper left). The nonobviousness argument is that all prior art spoke only to methods of treating sub-hyperglyceredemic patients. pic.twitter.com/KA1OLklYOp
— Dr. Zoidberg 🇺🇦 (@psuvafan007) May 22, 2020
dammit - i duplicated one image. here is the non duplicate. $AMRN pic.twitter.com/Lo54hnOXSY
— Dr. Zoidberg 🇺🇦 (@psuvafan007) May 22, 2020
off label prescriptions
How could there be an amicus brief for generics before generics file their brief ?
That brings us back to my original question haha!
That wasn’t my question. BP is not the only source an amicus brief can come from. But one possible answer to your question would be if BP has any interest in acquiring AMRN you would think they would want to salvage the US market.
Does anyone know if amicus briefs are typically posted last minute or would they have posted any time this past week?
Thanks!
Tough to keep up with the posts here. A little late to the party on this one and I'm sure this has already been mentioned but curious to hear some opinions.
Since it's no longer a secret that patients with diabetes and cardiovascular related issues seem to have a tougher time with COVID, is Remdesivir and Vascepa possibly the match made in Heaven? Has anyone inquired with Investor Relations on this topic?